Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Headquartered in Franklin, Tennessee, Acadia Healthcare was established in January...
Headquartered in Franklin, Tennessee, Acadia He...
Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...
Chimerix is a development-stage biopharmaceutic...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
Biomerica, Inc. is a global biomedical company that develops, manufactures and mar...
Biomerica, Inc. is a global biomedical company ...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Join the National Investor Network and get the latest information with your interests in mind.